,7,8,9 Selumetinib is an MEK pathway inhibitor that has been FDA approved for plexiform neurofibromas in patients with neurofibromatosis type I.10,11 To the best of our knowledge, there is no published literature for the use of selumetinib for treating tumors in patients with NF2. This evidence concerns the gene NF2 and plexiform neurofibroma.